Fig. 3: Cytotoxicity studies with GPC-1 knockdown cell line.
From: Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer
a Flow cytometry of GPC-1 expression in a GPC-1-knockdown cell line (BxPC-3 KD-2-23) and a control cell line (BxPC-3 NC-11) using anti-GPC-1 monoclonal antibody. b Quantitative reverse transcription-PCR analysis of GPC-1 mRNA levels relative to β-actin in a GPC-1-knockdown cell line (BxPC-3 KD-2-23) and control cell lines (BxPC-3 and BxPC-3 NC-11). c BxPC-3, BxPC-3 NC-11 and BxPC-3 KD-2-23 were treated with GPC-1-ADC for 144 h. GPC-1-ADC had a lower growth inhibition effect of the GPC-1-knockdown cell line (BxPC-3 KD-2-23) than the parent BxPC-3 and the negative control cell line (BxPC-3 NC-11).
